NCT05336851 Emergency PWAS in Respiratory Infectious Disease
| NCT ID | NCT05336851 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Viral Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2023-04-11 |
| Primary Completion | 2028-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2023-04-11 with a primary completion date of 2028-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID). Phase 1 1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2 2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics
Eligibility Criteria
Inclusion Criteria: Patients eligible for enrolment include: With reference to previous inclusion criteria are: * Adults ≥18 years of age; AND * Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\*; AND * Informed consent. Note: scaRID is defined according to ALL three criteria: 1. Community acquired (not hospitalised for \<28 days); AND 2. Acute infection (defined as symptom onset \<8 days and any ONE of reported fever or chills or aural temperature \>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND 3. Probable respiratory infection - According to any ONE of: 1. new cough or new sputum production or 2. chest pain or 3. dyspnoea or 4. tachypnoea or 5. abnormal lung examination or 6. respiratory failure; or 7. physician's judgment (presenting with systemic or gastrointestinal symptoms). Control subjects will be drawn from two groups: * The worried well - adult patients with a National Early Warning Score (NEWS) \<3 and a temperature \<37.5°C. * Relatives or accompanying friends with no acute illness. Exclusion Criteria: * Refusal of consent; * Recent hospitalisation (\<28 days); * Enrolled in another clinical trial * Cellulitis; * Skin or orthopaedic infections; * Urinary tract infection; * Acute abdominal sepsis; * Sexual transmitted disease; * Human immunodeficiency virus (HIV) infection; * Immunocompromised/potential neutropenic fever; * Solid organ or haematopoietic stem-cell transplant within the previous 90 days; * Active graft-versus-host disease or bronchiolitis obliterans; * Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases; * Stroke; * Toxidrome; * Non-organic acute psychosis.
Contact & Investigator
Timothy H Rainer, MD
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT05336851 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Viral Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05336851 currently recruiting?
Yes, NCT05336851 is actively recruiting participants. Contact the research team at thrainer@hku.hk for enrollment information.
Where is the NCT05336851 trial being conducted?
This trial is being conducted at Hong Kong, China.
Who is sponsoring the NCT05336851 clinical trial?
NCT05336851 is sponsored by The University of Hong Kong. The principal investigator is Timothy H Rainer, MD at The University of Hong Kong. The trial plans to enroll 2,000 participants.